Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus chemotherapy in second-line metastatic colorectal cancer
NCT00700102Phase 3Completed
- Sponsor
- Roche
- Start
- Feb 2006
- Primary completion
- May 2013
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial of bevacizumab in colorectal cancer (metastatic) (mCRC), sponsored by Roche. Primary endpoint: Overall Survival at 6.5 years. Started Feb 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT00700102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00700102.